Neil Fisher

Neil Fisher

Auto-generated profile, based on publicly available information

Neil Fisher

Russells Hall Hospital, Dudley, United Kingdom

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 1995 in The Lancet
Verified
Journal Article
Closed access
NKNelson Kung
Nelson Kung
NFNeil Fisher
Neil Fisher
BGBridget Gunson
Bridget Gunson
MHMark Hastings
Mark Hastings
DMDavid Mutimer
David Mutimer

31 May 2023 in JMIR Research Protocols
Verified
Journal Article
Open access
YHYaqza Hussain
Yaqza Hussain
ABAyman Bannaga
Ayman Bannaga
NFNeil Fisher
Neil Fisher
AKAshwin Krishnamoorthy
Ashwin Krishnamoorthy
PKPeter Kimani
Peter Kimani
RARamesh Arasaradnam
Ramesh Arasaradnam
Background: Hepatocellular cancer (HCC) is associated with high mortality, and early diagnosis leads to better survival. Patients with cirrhosis, especially due to nonalcoholic fatty liver disease and viral hepatitis, are at higher risk of developing HCC and form the main screening group. The current screening methods for HCC (6-monthly screening with serum alpha fetoprotein and ultrasound liver) have low sensitivity; hence, there is a need for better screening markers for HCC. Objective: Our study, TENDENCY, aims to validate the novel screening markers (methylated septin 9, urinary volatile organic compounds, and urinary peptides) for HCC diagnosis and study these noninvasive biomarkers in liver disease. Methods: This is a multicenter, nested case-control study, which involves comparing the plasma levels of methylated septin 9 between confirmed HCC cases and patients with cirrhosis (control group). It also includes the comparison of urine samples for the detection of HCC-specific volatile organic compounds and peptides. Based on the findings of a pilot study carried out at University Hospital Coventry & Warwickshire, we estimated our sample size to be 308 (n=88, 29% patients with HCC; n=220, 71% patients with cirrhosis). Urine and plasma samples will be collected from all participants and will be frozen at –80 °C until the end of recruitment. Gas chromatography–mass spectrometry will be used for urinary volatile organic compounds detection, and capillary electrophoresis–mass spectrometry will be used for urinary peptide identification. Real-time polymerase chain reaction will be used for the qualitative detection of plasma methylated septin 9. The study will be monitored by the Research and Development department at University Hospital Coventry & Warwickshire. Results: The recruitment stage was completed in March 2023. The TENDENCY study is currently in the analysis stage, which is expected to finish by November 2023. Conclusions: There is lack of effective screening tests for hepatocellular cancer despite higher mortality rates. The application of more sensitive plasma and urinary biomarkers for hepatocellular cancer screening in clinical practice will allow us to detect the disease at earlier stages and hence, overall, improve HCC outcomes. International Registered Report Identifier (IRRID): DERR1-10.2196/44264

19 June 2022 in Gut
Verified
Conference Paper
Closed access
PDF file
NFNeil Fisher
Neil Fisher
JFJohn Frost
John Frost
Introduction Transnasal upper GI endoscopy has become popular in recent years with some tolerability advantages compared with conventional endoscopy. Several published case series have also demonstrated success with PEG insertion via transnasal access for higher risk cases such as neurodegenerative disease and stricturing aerodigestive malignancies. We have reviewed our experience here Methods For patients with neurodegenerative disease we do T-PEGs using Freka disk-retained PEG kits, with capture of the pull-through thread in the stomach using biopsy forceps and removal via the nostril. Naso-oral transfer of the traction thread is done, followed by a conventional pull-through technique. For patients with aerodigestive malignancy we do T-PEGs with a Pexact ‘push-PEG’ gastropexy device and a balloon gastrostomy tube A prospective database is maintained and was used for this review Results From 2018 to 2022 inclusive, 36 T-PEGs have been done. Indications were neurodegenerative disease (18 cases, mostly motor neurone disease and done with pull-through kits); cancer (14 cases, all oesophageal or oro-pharyngeal cancer and all but one done with Pexact); stroke (3) and PEG exchange 1 (all pull-through). In the neurodegenerative case series, around half (8/18) of were done with midazolam only (median dose 1mg), the remaining cases were done without sedation. In the cancer case series most were done with midazolam and pethidine sedation (median doses 2 and 25mg respectively). All cases were done as day cases. There were no procedural failures or technical complications. One patient was readmitted with peritonism which settled with conservative management. Overall 30-day mortality was 1/34 (a cancer case). Informal feedback indicates good tolerability for T-PEGs Summary and Conclusions We have adopted the procedure of T-PEGs for selected indications with high success and low complication rates. This has allowed local provision of a PEG service for cases that may have otherwise required more demanding or higher-risk alternative options for nutritional support.


19 June 2022 in Gut
Verified
Conference Paper
Closed access
PDF file
AIAsem Ismail
Asem Ismail
SISauid Ishaq
Sauid Ishaq
RMRizwan Mahmood
Rizwan Mahmood
JFJohn Frost
John Frost
SSShanika De Silva
Shanika De Silva
NFNeil Fisher
Neil Fisher
Introduction Physician Associates (PAs) are part of the solution for addressing NHS healthcare shortages. One of the ways PAs can be utilised in gastroenterology is in supporting a day-case paracentesis service. We have looked at our outcomes of having a PA led ambulatory service in a district general hospital. Methods A senior PA underwent training in paracentesis on the gastroenterology ward, and after achieving competency, was commissioned to lead the ambulatory service on our day case ward. A retrospective analysis of service performance from 2018 to 2020 was done. The main outcome measures were number of procedures performed, reasons for cancelled procedures and complications post-procedure; these details were obtained from electronic discharge letters. A random selection of patients (n=56) were also asked to complete a paper survey on their experience of the service. Results A total of 372 elective ambulatory procedures were performed over the study period (76 in 2018, 118 in 2019 and 178 in 2020). The majority of these procedures (n=312, 83.9%) were done for cirrhotic patients. Successful procedures that were completed with no complications were 358 (The main complication post-procedure was that of ascites leakage at the entry site (n=11, 2.7%). Direct procedure related complications leading to unplanned admissions was 3 out of 372 cases (0.81%). These were one case of post-procedural bleeding, one case of persistent hypotension and one of significant pain resulting in the premature removal of the drain. There were no cases of viscus perforation. Twelve patients were admitted for reasons not relating to the procedure itself (n=6 for deranged blood tests, n=6 decompensated clinically i.e. encephalopathy). From the patients that were surveyed on their experience (n=56), 95% rated their overall experience as excellent or good. 91% of patients rated the technical ability of the performing practitioner as excellent and 93% rated the explanation of the procedure as excellent. Conclusions Having a PA as a permanent team member who is always available without on-call responsibilities has helped in enabling the service to expand year on year. With appropriate training, having a PA led service may be both safe and effective, with overwhelmingly positive patient satisfaction.

22 November 2022 in JMIR Preprints
Verified
Preprint
Open access
YHYaqza Hussain
Yaqza Hussain
ABAyman Bannaga
Ayman Bannaga
NFNeil Fisher
Neil Fisher
AKAshwin Krishnamoorthy
Ashwin Krishnamoorthy
PKPeter Kimani
Peter Kimani
RARamesh Arasaradnam
Ramesh Arasaradnam
BACKGROUND Hepatocellular cancer (HCC) is associated with high mortality, and early diagnosis leads to better survival. Patients with cirrhosis, especially due to nonalcoholic fatty liver disease and viral hepatitis, are at higher risk of developing HCC and form the main screening group. The current screening methods for HCC (6-monthly screening with serum alpha fetoprotein and ultrasound liver) have low sensitivity; hence, there is a need for better screening markers for HCC. OBJECTIVE Our study, TENDENCY, aims to validate the novel screening markers (methylated septin 9, urinary volatile organic compounds, and urinary peptides) for HCC diagnosis and study these noninvasive biomarkers in liver disease. METHODS This is a multicenter, nested case-control study, which involves comparing the plasma levels of methylated septin 9 between confirmed HCC cases and patients with cirrhosis (control group). It also includes the comparison of urine samples for the detection of HCC-specific volatile organic compounds and peptides. Based on the findings of a pilot study carried out at University Hospital Coventry & Warwickshire, we estimated our sample size to be 308 (n=88, 29% patients with HCC; n=220, 71% patients with cirrhosis). Urine and plasma samples will be collected from all participants and will be frozen at –80 °C until the end of recruitment. Gas chromatography–mass spectrometry will be used for urinary volatile organic compounds detection, and capillary electrophoresis–mass spectrometry will be used for urinary peptide identification. Real-time polymerase chain reaction will be used for the qualitative detection of plasma methylated septin 9. The study will be monitored by the Research and Development department at University Hospital Coventry & Warwickshire. RESULTS The recruitment stage was completed in March 2023. The TENDENCY study is currently in the analysis stage, which is expected to finish by November 2023. CONCLUSIONS There is lack of effective screening tests for hepatocellular cancer despite higher mortality rates. The application of more sensitive plasma and urinary biomarkers for hepatocellular cancer screening in clinical practice will allow us to detect the disease at earlier stages and hence, overall, improve HCC outcomes. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/44264